PT - JOURNAL ARTICLE AU - Zhang, Jia-Yuan AU - Hamey, Fiona AU - Trzupek, Dominik AU - Mickunas, Marius AU - Lee, Mercede AU - Godfrey, Leila AU - Yang, Jennie H.M. AU - Pekalski, Marcin L AU - Kennet, Jane AU - Waldron-Lynch, Frank AU - Evans, Mark AU - Tree, Timothy I. M. AU - Wicker, Linda S. AU - Todd, John A. AU - Ferreira, Ricardo C. TI - Low-dose IL-2 reduces IL-21<sup>+</sup> T cells and induces a long-lived anti-inflammatory gene expression signature inversely modulated in COVID-19 patients AID - 10.1101/2022.04.05.22273167 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.05.22273167 4099 - http://medrxiv.org/content/early/2022/04/05/2022.04.05.22273167.short 4100 - http://medrxiv.org/content/early/2022/04/05/2022.04.05.22273167.full AB - Despite early clinical success, the mechanisms of action of low-dose interleukin-2 (LD-IL-2) immunotherapy remain only partly understood. Here, we examine the effects of interval administration of low-dose recombinant IL-2 (iLD-IL-2) using high-resolution, single-cell multiomics. We confirmed that iLD-IL-2 selectively expands thymic-derived FOXP3+HELIOS+ Tregs and CD56br NK cells, and provide new evidence for an IL-2-induced reduction of highly differentiated IL-21-producing CD4+ T cells. We also discovered that iLD-IL-2 induces an anti-inflammatory gene expression signature, which was detected in all T and NK cell subsets even one month after treatment. The same signature was present in COVID-19 patients, but in the opposite direction. These findings indicate that the sustained Treg and CD56br NK cell increases induced by our 4-week iLD-IL2 treatment create a long-lasting and global anti-inflammatory environment, warranting further investigations of the potential clinical benefits of iLD-IL-2 in immunotherapy, including the possibility of reversing the pro-inflammatory environment in COVID-19 patients.Competing Interest StatementFWL is employed by Vertex Pharmaceuticals; JAT is a member of the GSK Human Genetics Advisory Board.Clinical TrialNCT02265809Funding StatementThis work was supported by the Sir Jules Thorn Trust (13/JTA (OCT2013/DR/1044)), the JDRF (1-SRA-2019-657-A-N), and the NIHR Cambridge Biomedical Research Centre. The Diabetes and Inflammation Laboratory was supported by a strategic award from the Wellcome (107212/A/15/Z) and the JDRF (4-SRA-2017-473-A-A). JYZ was supported by the China Scholarship Council-University of Oxford Scholarship. The research was supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z with funding from the NIHR Oxford BRC. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval was obtained from the Health Research Authority, National Research Ethics Service (14/EE/1057), London, United Kingdom. The trial was registered at the International Standard Randomised Controlled Trial Number Register (ISRCTN40319192) and ClinicalTrials.gov (NCT02265809).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors